has been cited by the following article(s):
[1]
|
The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States
Journal of Medical Economics,
2017
DOI:10.1080/13696998.2016.1225577
|
|
|
[2]
|
Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer
Journal of Medical Economics,
2017
DOI:10.1080/13696998.2016.1229670
|
|
|